Fig 3.
Disease-free survival (DFS) and overall survival (OS) comparing patients assigned to CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy with patients assigned to no CMF chemotherapy with triple-negative (A,D), human epidermal growth factor receptor 2 (HER2) –positive, endocrine receptor–absent (B,E), and endocrine receptor–present (C,F) subtypes. Pts, patients; yr, year.
